Seeking Alpha

The FDA grants a priority review designation to Exelixis' (EXEL +8.6%) cabozantinib treatment...

The FDA grants a priority review designation to Exelixis' (EXEL +8.6%) cabozantinib treatment for medullary thyroid cancer and set an action date of November 29. In preclinical studies, cabozantinib killed tumor cells, lowered metastases, and inhibited the formation of the new blood vessels needed to support tumor growth. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|